The DOI matches its Crossref record; 289 of the 291 references it cites were found in a registry or an index.
HCN Channel Targets for Novel Antidepressant Treatment
Open accessAbstract
Major depressive disorder (MDD) is a chronic and potentially life threatening illness that carries a staggering global burden. Characterized by depressed mood, MDD is often difficult to diagnose and treat owing to heterogeneity of syndrome and complex etiology. Contemporary antidepressant treatments are based on improved monoamine-based formulations from serendipitous discoveries made > 60 years ago. Novel antidepressant treatments are necessary, as roughly half of patients using available antidepressants do not see long-term remission of depressive symptoms. Current development of treatment options focuses on generating efficacious antidepressants, identifying depression-related neural substrates, and better understanding the pathophysiological mechanisms of depression. Recent insight into the brain's mesocorticolimbic circuitry from animal models of depression underscores the importance of ionic mechanisms in neuronal homeostasis and dysregulation, and substantial evidence highlights a potential role for ion channels in mediating depression-related excitability changes. In particular, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are essential regulators of neuronal excitability. In this review, we describe seminal research on HCN channels in the prefrontal cortex and hippocampus in stress and depression-related behaviors, and highlight substantial evidence within the ventral tegmental area supporting the development of novel therapeutics targeting HCN channels in MDD. We argue that methods targeting the activity of reward-related brain areas have significant potential as superior treatments for depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Available evidence suggests a plausible HCN-linked phenotype involving cognitive inertia and slowed affective transitions, but this remains a translational hypothesis rather than a validated treatment mechanism [290,291].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [290]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“meta-analytic datasets suggest comparable efficacy to several standard treatments when dose and resistance are considered, with emerging hints of cognitive improvement alongside mood change [290]”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [290]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Clinically, dorsolateral prefrontal transcranial direct current stimulation (tDCS) yields the largest benefits in patients with psychomotor retardation and executive disturbance”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [290]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–289 of 289
A Pilot Trial of Adjunctive Gabapentin in the Treatment of Bipolar Disorder
McElroy, S. L., Soutullo, C. A., Keck, P. E., & Kmetz, G. F. (1997) · Annals of Clinical Psychiatry · doi:10.1023/a:1026257303275 · Cited by 99
Lamotrigine as an Augmentation Agent in Treatment-Resistant Depression
Barbee, J. G., & Jamhour, N. J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0813 · Cited by 98
Zhang, K., Xu, T., Yuan, Z., Wei, Z., Yamaki, V. N., Huang, M., Huganir, R. L., & Cai, X. (2016) · Science Signaling · doi:10.1126/scisignal.aai7884 · Cited by 98
Gamo, N. J., Lur, G., Higley, M. J., Wang, M., Paspalas, C. D., Vijayraghavan, S., Yang, Y., Ramos, B. P., Peng, K., Kata, A., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.01.009 · Cited by 97
Brewster, A. L., Chen, Y., Bender, R. A., Yeh, A., Shigemoto, R., & Baram, T. Z. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhk021 · Cited by 96
Thuault, S., Malleret, G., Constantinople, C. M., Nicholls, R. E., Chen, I., Zhu, J., Panteleyev, A. A., Vronskaya, S., Nolan, M. F., Bruno, R. M., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2427-12.2013 · Cited by 96
Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients
Karam‐Hage, M., & Brower, K. J. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2003.01161.x · Cited by 96
Lamotrigine in Patients With Bipolar Disorder and Cocaine Dependence
Brown, E. S., Nejtek, V. A., Perantie, D. C., Orsulak, P. J., & Bobadilla, L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0213 · Cited by 89
Gabapentin Treatment of Mood Disorders
Ghaemi, S. N., Katzow, J. J., Desai, S. P., & Goodwin, F. K. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0805 · Cited by 88
Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
Arnsten, A. F. T., & Jin, L. E. (2012) · Europe PMC (PubMed Central) · Cited by 86
Gabapentin Treatment for Insomnia Associated With Alcohol Dependence
Karam‐Hage, M., & Brower, K. J. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.151 · Cited by 86
Santoro, B., Hu, L., Liu, H., Saponaro, A., Pian, P., Piskorowski, R. A., Moroni, A., & Siegelbaum, S. A. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5707-10.2011 · Cited by 84
Acute Treatment of Bipolar Depression with Gabapentin
Young, L. T., Robb, J. C., Patelis‐Siotis, I., MacDonald, C., & Joffe, R. T. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00305-3 · Cited by 84
Borderline personality disorder in patients with bipolar disorder and response to lamotrigine
Preston, G. A., Marchant, B. K., Reimherr, F. W., Strong, R. E., & Hedges, D. W. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00358-0 · Cited by 82
Walden, J., Heßlinger, B., van Calker, D., & Berger, T. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979570 · Cited by 81
Barbee, J. G., Thompson, T. R., Jamhour, N. J., Stewart, J. W., Conrad, E. J., Reimherr, F. W., Thompson, P. M., & Shelton, R. C. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05355gre · Cited by 78
Characteristics of HCN Channels and Their Participation in Neuropathic Pain
Jiang, Y., Sun, Q., Tu, H., & Wan, Y. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9717-6 · Cited by 75
Bender, R. A., Kirschstein, T., Kretz, O., Brewster, A. L., Richichi, C., Rüschenschmidt, C., Shigemoto, R., Beck, H., Frotscher, M., & Baram, T. Z. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4699-06.2007 · Cited by 75
Lamotrigine in Psychiatric Disorders
Reid, J. G., Gitlin, M. J., & Altshuler, L. L. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08046 · Cited by 73
Lamotrigine Treatment of Refractory Bipolar Disorder
Fogelson, D. L., & Sternbach, H. A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0607b · Cited by 72
A Pilot Trial of Adjunctive Gabapentin in the Treatment of Bipolar Disorder
McElroy, S. L., Soutullo, C. A., Keck, P. E., et al. (1997) · Annals of Clinical Psychiatry · doi:10.3109/10401239709147781 · Cited by 72
Nierenberg, A. A., Ostacher, M. J., Huffman, J. C., Ametrano, R. M., Fava, M., & Perlis, R. H. (2008) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e31816b5034 · Cited by 70
Anticonvulsants in the Treatment of Major Depressive Disorder
Vigo, D., & Baldessarini, R. J. (2009) · Harvard Review of Psychiatry · doi:10.1080/10673220903129814 · Cited by 69
Noam, Y., Zha, Q., Phan, L., Wu, R.-L., Chetkovich, D. M., Wadman, W. J., & Baram, T. Z. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.070391 · Cited by 68
Chen, C. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03174.x · Cited by 68
Stafstrom, C. E., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3561 · Cited by 67
An open label study of gabapentin in the treatment of acute mania
Erfurth, A., Kammerer, C., Grunze, H., Normann, C., & Walden, J. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)00010-7 · Cited by 66
Treatment of acute mania with gabapentin
Stanton, S. P., Keck, P. E., & McElroy, S. L. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.2.287a · Cited by 66
Effects of lamotrigine in patients with bipolar disorder and alcohol dependence
Rubio, G., López‐Muñoz, F., & Alamo, C. (2006) · Bipolar Disorders · doi:10.1111/j.1399-5618.2006.00292.x · Cited by 64
Lamotrigine for the treatment of bipolar disorder: a clinical case series
Suppes, T. M., Brown, E. S., McElroy, S. L., Keck, P. E., Nolen, W. A., Kupka, R., Frye, M. A., Denicoff, K. D., Altshuler, L. L., Leverich, G. S., et al. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00077-9 · Cited by 64
Gabapentin Therapy in Psychiatric Disorders
Berlin, R. K., Butler, P. M., & Perloff, M. D. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15r01821 · Cited by 64
Han, Y. S., Noam, Y., Lewis, A. S., Gallagher, J. J., Wadman, W. J., Baram, T. Z., & Chetkovich, D. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.236125 · Cited by 63
The Current Understanding of Lamotrigine as a Mood Stabilizer
Hahn, C.-G., Gyulai, L., Baldassano, C. F., & Lenox, R. H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0610 · Cited by 63
van der Loos, M. L. M., Mulder, P. G. H., Hartong, E. G. T. M., Blom, M. B. J., Vergouwen, A. C. M., van Noorden, M. S., Timmermans, M. A. Y., Vieta, E., Nolen, W. A., & for the LamLit Study Group* (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00887.x · Cited by 61
Input resistance is voltage dependent due to activation of Ih channels in rat CA1 pyramidal cells
Surges, R., Freiman, T. M., & Feuerstein, T. J. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20075 · Cited by 60
Premkumar, T. S., & Pick, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005962.pub2 · Cited by 59
Lamotrigine Augmentation of Serotonin Re-Uptake Inhibitors in Obsessive–Compulsive Disorder
Kumar, T. C. R., & Khanna, S. (2000) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2000.0751c.x · Cited by 59
Sotty, F., Damgaard, T. D., Montezinho, L. P., Mørk, A., Olsen, C., Bundgaard, C., & Husum, H. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146944 · Cited by 59
Bankston, J. R., Camp, S. S., DiMaio, F., Lewis, A. S., Chetkovich, D. M., & Zagotta, W. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201997109 · Cited by 57
Lamotrigine for bipolar disorder and comorbid cocaine dependence: A replication and extension study
Brown, E. S., Perantie, D. C., Dhanani, N., Beard, L., Orsulak, P. J., & Rush, A. J. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.02.001 · Cited by 57
Arencibia‐Albite, F., Paladini, C. A., Williams, J., & Jiménez‐Rivera, C. A. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.08.009 · Cited by 57
Gabapentin Augmentation for Fluoxetine-Treated Patients With Obsessive-Compulsive Disorder
Cora‐Locatelli, G., Greenberg, B. D., Martin, J. D., & Murphy, D. L. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0907d · Cited by 56
Comparative efficacy of combination drug therapy in refractory epilepsy
Poolos, N. P., Warner, L. N., Humphreys, S. Z., & Williams, S. P. (2011) · Neurology · doi:10.1212/wnl.0b013e31823ed0dd · Cited by 55
Han, Y. S., Heuermann, R. J., Lyman, K. A., Fisher, D. W., Ismail, Q.-A., & Chetkovich, D. M. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.99 · Cited by 54
Stahl, S. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0601 · Cited by 52
Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder
Dencker, D., & Husum, H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.040 · Cited by 52
Fatigue and depression in multiple sclerosis.
Brannon, N., Labbate, L. A., & Huber, M. (2000) · PubMed · Cited by 52
Arnsten, A. F. T., & Wang, M. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103617 · Cited by 50
Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up
Leiberich, P. K., Nickel, M., Tritt, K., & Gil, F. P. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107084004 · Cited by 48
Vargas, G., & Lucero, M. T. (2002) · The Journal of Membrane Biology · doi:10.1007/s00232-001-0178-y · Cited by 48
Lamas, J. A. (1998) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s004240050653 · Cited by 48
Kalyoncu, A., Mırsal, H., Pektaş, Ö., Ünsalan, N., Tan, D., & Beyazyürek, M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051542 · Cited by 47
The Yin and Yang of the H-Channel and Its Role in Epilepsy
Poolos, N. P. (2004) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7597.2004.04101.x · Cited by 47
Brown, E. S., Sunderajan, P., Hu, L. T., Sowell, S. M., & Carmody, T. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.90 · Cited by 46
Houghton, K. T., Forrest, A., Awad, A. M. M., Atkinson, L. Z., Stockton, S., Harrison, P. J., Geddes, J. R., & Cipriani, A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013433 · Cited by 46
Williams, A. D., Jung, S., & Poolos, N. P. (2015) · The Journal of Physiology · doi:10.1113/jp270453 · Cited by 44
Specific bradycardic agents block the hyperpolarization-activated cation current in central neurons
Pape, H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90602-5 · Cited by 44
The clinical use of gabapentin in bipolar spectrum disorders
Carta, M. G., Hardoy, M. C., Hardoy, M. J., Grunze, H., & Carpiniello, B. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00046-0 · Cited by 43
Inyushin, M. Y., Arencibia‐Albite, F., Vázquez‐Torres, R., Vélez-Hernández, M. E., & Jiménez‐Rivera, C. A. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.052 · Cited by 43
TRIP8b-Independent Trafficking and Plasticity of Adult Cortical Presynaptic HCN1 Channels
Huang, Z., Luján, R., Hernández, J. M., Lewis, A. S., Chetkovich, D. M., & Shah, M. M. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-12.2012 · Cited by 41
Yan, H., Li, Q., Fleming, R. L., Madison, R. D., Wilson, W. A., & Swartzwelder, H. S. (2008) · Journal of Neurophysiology · doi:10.1152/jn.90557.2008 · Cited by 40
Aoki, C. J., Venkatesan, C., & Kurose, H. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60862-5 · Cited by 33
A Preliminary Investigation of Lamotrigine for Cocaine Abuse in HIV-Seropositive Patients
Margolin, A., Avants, S. K., Philippis, D. D., & Kosten, T. R. (1998) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999809001700 · Cited by 33
Rebound Psychiatric and Physical Symptoms After Gabapentin Discontinuation
Cora‐Locatelli, G., Greenberg, B. D., Martin, J. D., & Murphy, D. L. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0308a · Cited by 29
Ivković, M., Damjanović, A., Jovanović, A., Cvetić, T., & Jašović‐Gašić, M. (2009) · PubMed · Cited by 28
Gabapentin in the Treatment of Posttraumatic Stress Disorder
Berigan, T. R. (2000) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v02n0307 · Cited by 28
Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channels and Pain
Dunlop, J., Vasilyev, D., Lu, P., Cummons, T. A., & Bowlby, M. R. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788186281 · Cited by 28
How Should Primary Care Doctors Select Which Antidepressants to Administer?
Gartlehner, G., Thaler, K. J., Hill, S., & Hansen, R. A. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0283-x · Cited by 28
Atalay, H., Solak, Y., Bıyık, Z., Gaipov, A., Güney, F., & Türk, S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0080-2 · Cited by 28
HCN1 Channels: A New Therapeutic Target for Depressive Disorders?
Shah, M. M. (2012) · Science Signaling · doi:10.1126/scisignal.2003593 · Cited by 26
Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder
Kelmendi, B., Beltrame, M. H., McIntosh, A. M., Hilt, L. M., George, E. D., Kitchen, R. R., Carlyle, B. C., Pittenger, C., Coric, V., Nolen–Hoeksema, S., et al. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.04.026 · Cited by 26
Ivabradine: Current and Future Treatment of Heart Failure
Thorup, L., Simonsen, U., Grimm, D. G., & Hedegaard, E. R. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12784 · Cited by 25
Molecular Regulation and Pharmacology of Pacemaker Channels
Bois, P., Guinamard, R., Chemaly, A. E., Faivre, J., & Bescond, J. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207781368729 · Cited by 24
Connor, D., Arnsten, A., Pearson, G., & Greco, G. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.930437 · Cited by 23
Han, Y. S., Lyman, K. A., Clutter, M., Schiltz, G. E., Ismail, Q.-A., Prados, D. B., Luan, C.-H., & Chetkovich, D. M. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115589590 · Cited by 20
Lamotrigine for treatment-refractory bipolar disorder
Labbate, L. A., & Rubey, R. N. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1317a · Cited by 19
1983 Annual meeting of the Society of Biological Psychiatry
(1983) · Journal of Affective Disorders · doi:10.1016/0165-0327(83)90014-9 · Cited by 19
Ivabradine: Beyond heart rate control
Riccioni, G., Vitulano, N., & D’Orazio, N. (2009) · Advances in Therapy · doi:10.1007/s12325-008-0130-y · Cited by 18
Jump-starting natural resilience reverses stress susceptibility
Friedman, A. K. (2014) · Science · doi:10.1126/science.1260781 · Cited by 17
Short- and long-term plasticity in CA1 neurons from mice lacking h-channel auxiliary subunit TRIP8b
Brager, D. H., Lewis, A. S., Chetkovich, D. M., & Johnston, D. (2013) · Journal of Neurophysiology · doi:10.1152/jn.00218.2013 · Cited by 17
Long-Term Lamotrigine Adjunctive to Antipsychotic Monotherapy in Schizophrenia: Further Evidence
Kolivakis, T., Beauclair, L., Margolese, H. C., & Chouinard, G. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900411 · Cited by 14
Safety and tolerability of anticonvulsant medication in bipolar disorder
Pichler, E. M., Hattwich, G., Grunze, H., & Muehlbacher, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1088001 · Cited by 13
Nakamura, A. M., Mihara, K., Nagai, G., Kagawa, S., Suzuki, T., Nemoto, K., & Kondo, T. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000279 · Cited by 13
McIntosh, A. M., Simen, A. A., Evans, K. L., Hall, J., MacIntyre, D. J., Blackwood, D., Morris, A. D., Smith, B. H., Dominiczak, A. F., Porteous, D. J., et al. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00116 · Cited by 11
He, W., Xu, X., Lv, Q., & Guo, L. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-014-0047-8 · Cited by 7
Ivabradine: A Current Overview
Guha, K., Allen, C. J., Hartley, A., & Sharma, R. (2016) · Current Clinical Pharmacology · doi:10.2174/1574884711666161026092420 · Cited by 6
Han, Y. S., Lyman, K. A., Clutter, M., Schiltz, G. E., Ismail, Q.-A., Cheng, X., Luan, C.-H., & Chetkovich, D. M. (2016) · Journal of Visualized Experiments · doi:10.3791/54540 · Cited by 6
Mihara, K., Nakamura, A. M., Nemoto, K., Nagai, G., Kagawa, S., Suzuki, T., & Kondo, T. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12376 · Cited by 2
Han, Y., Lyman, K. A., Clutter, M., Schiltz, G. E., Ismail, Q.-A., Cheng, X., Luan, C., & Chetkovich, D. M. (2016) · Journal of Visualized Experiments · doi:10.3791/54540-v · Cited by 2
Flagged first, then by citations
2 of the 291 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Brannon, 2000, Gabapentin treatment for posttraumatic stress disorder, Can J Psychiatry., 45, 84
Cited by
Sorted by citations
Neurobiology of Resilience: Interface Between Mind and Body
Cathomas, F., Murrough, J. W., Nestler, E. J., Han, M.-H., & Russo, S. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.011 · Cited by 296
“It is known that RSDS increases the excitatory Ih current in VTA DA neurons of susceptible mice, and induces even greater increases in Ih in these neurons of resilient mice (51) (53) (54).”
BackgroundSelf-citationRole of Mesolimbic Brain-Derived Neurotrophic Factor in Depression
Koo, J. W., Chaudhury, D., Han, M.-H., & Nestler, E. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.020 · Cited by 112
Self-citationSantoro, B., & Shah, M. M. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023356 · Cited by 108
HCN2 channels in the ventral tegmental area regulate behavioral responses to chronic stress
Zhong, P., Vickstrom, C. R., Liu, X., Hu, Y., Yu, L., Yu, H.-G., & Liu, Q.-S. (2018) · eLife · doi:10.7554/elife.32420 · Cited by 99
“…CMS reduced action potential (AP) firing in VTA dopamine neurons (Chang and Grace, 2014; Moreines et al., 2017; Tye et al., 2013), whereas susceptibility to CSDS was accompanied by an increase in AP firing (Cao et al., 2010; Chaudhury et al., 2013; Krishnan et al., 2007; Ku and Han, 2017).”
BackgroundUnderstanding Lamotrigine’s Role in the CNS and Possible Future Evolution
Costa, B., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076050 · Cited by 79
Metadata
- Authors
- Ku, S. M., & Han, M.-H.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Han, Ming-Hu
- ORCID
- Han, Ming-Hu
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 14
- Issue
- 3
- Pages
- 698-715
- ISSN
- 1878-7479 (ISSN-L)
- PMC
- PMC5509632
- OpenAlex
- W2619412584
- Cited by
- 54
- References
- 291
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 9 · 2022: 4 · 2021: 5 · 2020: 9 · 2019: 4 · 2018: 4 · 2017: 2
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neurotherapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R21MH112081, F31MH108326)
- Brain and Behavior Research Foundation (NARSAD)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- HCN channels, major depressive disorder, antidepressant drug development, neuronal excitability, mesocorticolimbic circuitry, prefrontal cortex, hippocampus, ventral tegmental area, stress
- MeSH terms
- Animals, Antidepressive Agents, Brain, Major Depressive Disorder, Humans, Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
